Compare
BioAtla, Inc. vs Intensity Therapeutics, Inc. vs Entera Bio Ltd. vs Outlook Therapeutics, Inc.
| Latest fiscal year | BioAtla, Inc. BCAB | Intensity Therapeutics, Inc. INTS | Entera Bio Ltd. ENTX | Outlook Therapeutics, Inc. OTLK |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-09-30 |
| Revenue | n/a | n/a | $42.0K | $1.41M |
| Revenue growth (YoY) | n/a | n/a | -76.8% | n/a |
| Gross margin | n/a | n/a | 0.0% | 4.0% |
| Operating margin | n/a | n/a | n/m | n/m |
| Net margin | n/a | n/a | n/m | n/m |
| Net income | -$59.61M | -$11.61M | -$11.44M | -$62.42M |
| EPS (Diluted) | -$1.01 | -$8.56 | $0.25 | -$1.79 |
| Operating cash flow | -$48.20M | -$9.23M | -$7.37M | -$51.83M |
| Free cash flow | n/a | n/a | -$7.48M | n/a |
| Cash & equivalents | $7.12M | $11.92M | $7.11M | $8.08M |
| Total assets | $13.83M | $14.10M | $15.99M | $18.58M |
| Total liabilities | $50.02M | $2.23M | $2.89M | $50.77M |
| Shareholders' equity | $36.19M | $11.88M | $13.10M | -$32.19M |
| Return on year-end equity | -164.7% | -97.7% | -87.3% | n/a |
| Shares outstanding | 63.46M | 2.52M | 46.18M | 53.89M |
Revenue, most recent five fiscal years
| Fiscal year | BioAtla, Inc. | Intensity Therapeutics, Inc. | Entera Bio Ltd. | Outlook Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $300.0K Ended 2021-12-31 | n/a | $42.0K Ended 2025-12-31 | $1.41M Ended 2025-09-30 |
| 1 year earlier | n/a | n/a | $181.0K Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | n/a | $0 Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $134.0K Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $571.0K Ended 2021-12-31 | n/a |